The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

Launched by 4TH MILITARY CLINICAL HOSPITAL WITH POLYCLINIC, POLAND · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how using muscle relaxants during a specific heart procedure called electroporation ablation (PFA) can help protect patients from muscle damage. The goal is to make the PFA procedure safer, improve recovery time, and reduce any harm to the heart muscle during the process. Researchers are currently recruiting participants who need this heart procedure and can provide consent to join the study.

To be eligible, participants should be between the ages of 65 and 74 and must need the PFA procedure for heart issues. However, those who have allergies to certain anesthesia drugs, specific genetic muscle diseases, or who cannot agree to participate will not be included. If you join the trial, you can expect to receive standard care while also contributing to important research that could help many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation
• Exclusion Criteria:
• • Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.